Neuprex is blowing in the wind

Zephyr Sciences Inc.'s first deal since its formation in the summer of 2003 underscores in bold the reprofiling concept, as the company is taking on a compound that had been the focus of two biotech efforts in the early 1990s and has failed in two different sets of Phase III trials. But Zephyr

Read the full 539 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE